These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22661622)

  • 1. Probiotics in the treatment of the liver diseases.
    Kirpich IA; McClain CJ
    J Am Coll Nutr; 2012 Feb; 31(1):14-23. PubMed ID: 22661622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probiotics as an emerging therapeutic strategy to treat NAFLD: focus on molecular and biochemical mechanisms.
    Iacono A; Raso GM; Canani RB; Calignano A; Meli R
    J Nutr Biochem; 2011 Aug; 22(8):699-711. PubMed ID: 21292470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.
    Huang W; Kong D
    Biomed Pharmacother; 2021 Mar; 135():111235. PubMed ID: 33561650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia.
    Xue L; He J; Gao N; Lu X; Li M; Wu X; Liu Z; Jin Y; Liu J; Xu J; Geng Y
    Sci Rep; 2017 Mar; 7():45176. PubMed ID: 28349964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives.
    Malaguarnera G; Giordano M; Nunnari G; Bertino G; Malaguarnera M
    World J Gastroenterol; 2014 Nov; 20(44):16639-48. PubMed ID: 25469033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Probiotics in non-alcoholic fatty liver disease: which and when.
    Abenavoli L; Scarpellini E; Rouabhia S; Balsano C; Luzza F
    Ann Hepatol; 2013; 12(3):357-63. PubMed ID: 23619251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.
    Suk KT; Kim DJ
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):193-204. PubMed ID: 30791767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease.
    Paolella G; Mandato C; Pierri L; Poeta M; Di Stasi M; Vajro P
    World J Gastroenterol; 2014 Nov; 20(42):15518-31. PubMed ID: 25400436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease.
    Kaufmann B; Seyfried N; Hartmann D; Hartmann P
    Am J Physiol Gastrointest Liver Physiol; 2023 Jul; 325(1):G42-G61. PubMed ID: 37129252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prebiotics and Probiotics: Therapeutic Tools for Nonalcoholic Fatty Liver Disease.
    Mijangos-Trejo A; Nuño-Lambarri N; Barbero-Becerra V; Uribe-Esquivel M; Vidal-Cevallos P; Chávez-Tapia N
    Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of probiotics in treatment of nonalcoholic fatty liver disease].
    Chen M; Wang MC; Ni R; Wang J; Wang L; Wang GN; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2017 Jan; 25(1):77-80. PubMed ID: 28297790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?
    Li DY; Yang M; Edwards S; Ye SQ
    JPEN J Parenter Enteral Nutr; 2013 Nov; 37(6):787-93. PubMed ID: 23538296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut-liver axis, nutrition, and non-alcoholic fatty liver disease.
    Kirpich IA; Marsano LS; McClain CJ
    Clin Biochem; 2015 Sep; 48(13-14):923-30. PubMed ID: 26151226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of immunity and inflammatory gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics.
    Plaza-Diaz J; Gomez-Llorente C; Fontana L; Gil A
    World J Gastroenterol; 2014 Nov; 20(42):15632-49. PubMed ID: 25400447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics.
    Moludi J; Maleki V; Jafari-Vayghyan H; Vaghef-Mehrabany E; Alizadeh M
    Clin Exp Pharmacol Physiol; 2020 Jun; 47(6):927-939. PubMed ID: 31894861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of gut vascular barrier in experimental alcoholic liver disease and A. muciniphila supplementation.
    Grander C; Grabherr F; Spadoni I; Enrich B; Oberhuber G; Rescigno M; Tilg H
    Gut Microbes; 2020 Nov; 12(1):1851986. PubMed ID: 33382359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
    Hong M; Han DH; Hong J; Kim DJ; Suk KT
    Probiotics Antimicrob Proteins; 2019 Jun; 11(2):335-347. PubMed ID: 29687200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  Gut microbiota and nonalcoholic fatty liver disease.
    Machado MV; Cortez-Pinto H
    Ann Hepatol; 2012; 11(4):440-9. PubMed ID: 22700625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.